Current and future nanoparticle vaccines for COVID-19.
EBioMedicine
; 74: 103699, 2021 Dec.
Article
em En
| MEDLINE
| ID: mdl-34801965
ABSTRACT
COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with â¼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunogenicidade da Vacina
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
/
Lipossomos
Limite:
Humans
Idioma:
En
Revista:
EBioMedicine
Ano de publicação:
2021
Tipo de documento:
Article